Clinical outcomes following androgen receptor axis therapies (ARAT) among men with prostate cancer (PCa) having major cardiovascular diseases (CVDs) or extreme polypharmacy (EPP): A population based study.

5056Background: The safety of ARAT (Abiraterone acetate (AA) and Enzalutamide (ENZ)) among men with existing CVDs or EPP (≥10 concurrent medications) is unknown since patients with these conditions are often excluded from the clinical trials. This study was undertaken to fill these knowledge gaps. Methods: This population-based study identified PCa patients from the linked Surveillance, Epidemiology and End Result-Medicare files diagnosed during 1/1/1991-12/31/2013. The primary endpoint was 6-month overall mortality after drug initiation. CVDs include acute myocardial infarction (AMI), atrial fibrillation (AFIB), congestive heart failure (CHF), stroke, and ischemic heart disease (IHD). Cox proportional hazard models were used to assess the risk of 6-month mortality. Results: Our study included 3,116 patients treated with AA only or AA as first ARAT and 1,162 patients treated with ENZ only or ENZ as first ARAT. The characteristics of the patients treated with AA and ENZ were similar. The majority of patien...